The company’s MeMed BV product is the first FDA-cleared blood test system for accurately distinguishing between bacterial and viral infections in just 15 minutes. Bacterial and viral infections are often clinically identical and can lead to inappropriate patient management and antibiotic misuse.
Medica is one of the world’s largest medical B2B trade fairs. The startup competition recognizes outstanding innovations in digital health, aiming to take them to the next level by creating valuable connections and worldwide visibility.
Evaluation criteria include level of innovation; technological feasibility; marketing and go-to-market approach; potential time to market; commercial potential; and sustainability.
Winners get cash prizes as well as free marketing packages, global media coverage and expert advice for go-to-market strategy, scaling up, and more.
MeMed Commercial Director Yossi Horesh said, upon accepting the award, “For us, winning the competition is about recognition. It’s great to see that important judges really believe in our product. Hopefully, being part of this community and winning first prize will help us deliver faster and reach more patients as we tackle the problem of antimicrobial resistance and other conditions.”
The company is now developing MeMed Severity, designed to provide clinicians with an actionable result that helps answer the question of whether a patient is likely to have a severe infection that would cause his or her condition to deteriorate.